2016 Volume 65 Issue 1 Pages 45-50
We have analyzed chronic hepatitis C virus (HCV) genotype, amino acid substitutions at positions 70 and 91 of the HCV core region (core aa 70 and core aa 91), the number of interferon-sensitivity-determining region (ISDR) mutations since December 2009, and drug resistance mutations in nonstructural (NS) 3 and NS5A since September 2014. In this study, we gathered the analysis results. Genotyping was as follows (n = 315): 1a: 3 (1.0%), 1b: 192 (61.0%), 2a: 80 (25.4%), 2b: 33 (10.5%), 3a: 1 (0.3%), 3b: 1 (0.3%), and mixed type: 5 (1.6%). Of 192 HCV-1b samples, 156 were analyzed in terms of core aa 70, core aa 91, and ISDR mutations. There were mutations in 60 samples at core aa 70 (38.5%) and in 48 samples at core aa 91 (30.8%). The samples with ISDR mutations of the wild (no mutation), intermediate (1–3 mutations), and mutant (≥ 4 mutations) types were 66 (42.3%), 77 (49.4%), and 13 (8.3%), respectively. Thirty-six of 94 samples at NS3 and 23 of 94 samples at NS5A showed drug resistance mutations (38.3% and 24.5%, respectively). A more detailed effect prediction of HCV treatment was enabled by these genomic analyses.
